|
|
 |
|
Viewing report
|
|
|
|
Pipeline and Commercial Insight: Testosterone Replacement Therapy - Topical formulations drive market growth
Datamonitor, Sep 2010, Pages: 29
Introduction
The testosterone replacement therapy market grew with an impressive compound annual growth rate [CAGR]: 24.3% from 2005 to 2009 to reach $838m sales. While these drugs can reverse the symptoms of testosterone deficiency rather efficaciously, only an estimated 5% of affected people receive treatment.
Scope
- Patient potential analysis across the seven major markets
- Review of the key needs supported by key opinion leaders
- Current and future market dynamics in the seven major markets, including analysis and forecast for current leading brands
- R&D pipeline analysis with detailed profiles and forecasts of key agents, including Eli Lilly's Axiron (testosterone)
Highlights
Testosterone preparations come in a variety of formulations including injections and transdermal ones. While gels dominate the market in the US, in the EU there is a preference for injectables due to cost constraints.
The US is by far the largest market for testosterone replacement drugs, with sales in excess of $800m and accounting for almost 96% of the total sales value in 2009 and showing the strongest growth.
The deal with Eli Lilly is advantageous for Acrux. Axiron (testosterone) is the first metered dose transdermal system to reach this market. Driven by Eli Lilly's experience in the men's health arena and its marketing and sales resources, Axiron uptake which will become the leading drug in 2019.
Reasons to Purchase
- Understand patient population dynamics
- Gain insight into the unmet needs of current testosterone treatment and to what extent pipeline drugs will address these issues
- Identify licensing opportunities based on company portfolio and market needs
Customers who bought this item also bought
Testosterone Replacement Therapy (TRT) - Global Strategic Business Report
Pipeline and Commercial Insight: Hormonal Replacement Therapy for Menopausal Symptoms - Safety fears continue to haunt the market
Pipeline and Commercial Insight: Neuropathic Pain - Pipeline setbacks prolong Pfizer's supremacy
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.
Pipeline and Commercial Insight: Urinary Incontinence - Marketing investment and niche positioning are key strategies for success
Pipeline and Commercial Insight: Alzheimer's Disease - Market cautiously awaits the first generation of disease-modifying therapies
Pipeline Insight: Epilepsy - Past successes hard to emulate in highly genericized market
Transdermal Pain Management to 2015: Markets, Demand Factors, Opportunities and Forecasts
Active Transdermal Delivery Systems: Evolving Technology, Expanding Opportunities
|
|
|
|
